<p>PROCEPT BioRobotics Corporation（纳斯达克股票代码：PRCT - 获取免费报告）的股票在周二上涨了 7.4%。该公司的股价最高达到 28.17 美元，最后交易价格为 28.4110 美元。在午盘交易中，约有 588,266 股成交，较日均成交量 1,533,480 股下降了 62%。该股票此前收盘价为 26.45 美元。</p>
<p>获取 <strong>PROCEPT BioRobotics</strong> 的最新动态：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>3 只被低估的机器人股票有望获得巨大收益</li>
</ul>
<p>几家研究公司对 PRCT 进行了评估。Oppenheimer 在 2 月 26 日的研究报告中重新发布了对 PROCEPT BioRobotics 股票的 “市场表现” 评级。Robert W. Baird 在 3 月 6 日的研究报告中开始覆盖 PROCEPT BioRobotics。他们对该股票给予了 “中性” 评级，目标价为 30.00 美元。美国银行在 2 月 26 日的研究报告中将 PROCEPT BioRobotics 的评级从 “中性” 下调至 “表现不佳”，并将目标价从 38.00 美元下调至 20.00 美元。Leerink Partners 在 2 月 26 日的报告中将 PROCEPT BioRobotics 的目标价从 55.00 美元下调至 30.00 美元，并给予该公司 “跑赢大盘” 的评级。最后，Piper Sandler 在 4 月 30 日的研究报告中重申了 “增持” 评级，并将目标价从 28.00 美元上调至 35.00 美元。八位研究分析师对该股票给予了买入评级，四位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，PROCEPT BioRobotics 的共识评级为 “持有”，共识目标价为 41.45 美元。</p>
<p><strong>查看我们关于 PROCEPT BioRobotics 的最新报告</strong></p>
<h2>PROCEPT BioRobotics 股票上涨 7.7%</h2>
<ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
<p>该公司的市值为 16.2 亿美元，市盈率为-15.66，贝塔值为 0.83。公司的债务与股本比率为 0.15，流动比率为 6.73，速动比率为 5.51。该公司的 50 日移动平均线为 25.06 美元，200 日移动平均线为 29.17 美元。</p>
<p>PROCEPT BioRobotics（纳斯达克股票代码：PRCT - 获取免费报告）最近在 4 月 29 日公布了季度财报。该公司报告季度每股收益为（0.56 美元），低于市场共识预期的（0.55 美元）0.01 美元。PROCEPT BioRobotics 的净利润率为-31.82%，股本回报率为-27.70%。该公司在本季度的收入为 8313 万美元，而分析师的预期为 8052 万美元。在去年同期，该公司每股收益为（0.45 美元）。PROCEPT BioRobotics 的收入同比增长了 20.1%。卖方分析师预计 PROCEPT BioRobotics Corporation 在本财年的每股收益将为-1.53 美元。</p>
<h2>PROCEPT BioRobotics 的内部交易</h2>
<ul>
<li>为什么 Intuitive Surgical 的股票在医疗领域占据主导地位</li>
</ul>
<p>在其他新闻中，执行副总裁 Alaleh Nouri 在 3 月 19 日的交易中出售了 5,363 股 PROCEPT BioRobotics 的股票。该股票以平均价格 25.96 美元出售，总价值为 139,223.48 美元。出售后，该执行副总裁直接持有公司 105,354 股股票，价值约为 2,734,989.84 美元。此次交易使其持股减少了 4.84%。该出售在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事 Antal Rohit Desai 在 3 月 9 日的交易中购买了 98,699 股 PROCEPT BioRobotics 的股票。该股票以每股平均 24.55 美元的价格购买，总交易额为 2,423,060.45 美元。完成收购后，该董事直接持有公司 426,262 股股票，价值约为 10,464,732.10 美元。此次交易使其持股增加了 30.13%。有关此次购买的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士购买了 426,262 股公司股票，价值为 10,483,091 美元，并出售了 23,229 股，价值为 573,466 美元。内部人士持有公司 17.40% 的股份。</p>
<h2>机构投资者对 PROCEPT BioRobotics 的看法</h2>
<p>几家大型投资者最近增加或减少了对该股票的持股。Prosight Management LP 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 1,692.4%。Prosight Management LP 现在持有 138 万股公司股票，价值 4341.5 万美元，此前在上个季度又购买了 1,303,009 股。Alliancebernstein L.P.在第三季度将其在 PROCEPT BioRobotics 的持股增加了 58.6%。Alliancebernstein L.P.现在持有 3419784 股公司股票，价值 1.22052 亿美元，此前在上个季度又购买了 1,262,928 股。T. Rowe Price Investment Management Inc.在第四季度将其在 PROCEPT BioRobotics 的持股增加了 59.4%。T. Rowe Price Investment Management Inc.现在持有 3271408 股公司股票，价值 1.02919 亿美元，此前在上个季度又购买了 1,218,815 股。ArrowMark Colorado Holdings LLC 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 229.7%。ArrowMark Colorado Holdings LLC 现在持有 1128288 股公司股票，价值 4026.9 万美元，此前在上个季度又购买了 786,094 股。最后，Mackenzie Financial Corp 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 105.2%。Mackenzie Financial Corp 现在持有 1454434 股公司股票，价值 5190.9 万美元，此前在上个季度又购买了 745,778 股。89.46% 的股票由机构投资者持有。</p>
<h2>PROCEPT BioRobotics 公司简介</h2>
<p>（获取免费报告）</p>
<p>PROCEPT BioRobotics, Inc 是一家医疗设备公司，专注于开发和商业化用于治疗良性前列腺增生（BPH）的机器人系统。该公司的技术利用精密机器人和实时成像进行微创手术，旨在减少患者恢复时间，并改善与传统外科方法相比的临床结果。</p>
<p>该公司的旗舰产品 AquaBeam 机器人系统使用高速水射流选择性去除前列腺组织，同时保护周围健康结构。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 PROCEPT BioRobotics 更好的股票</li>
<li>AST SpaceMobile 因银河第一季度业绩不佳暴跌：垂直整合能拯救这家 SpaceX 竞争对手吗？</li>
<li>Axon 在财报发布后大涨，但仍比高点下跌超过 50%</li>
<li>可能重新定义苹果夏季反弹的事件</li>
<li>Hims &amp; Hers 股票在第一季度业绩不佳后暴跌：GLP-1 的转变足以推动复苏吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 PROCEPT BioRobotics 吗？</h2>
<p>在考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PROCEPT BioRobotics 并不在名单上。</p>
<p>虽然 PROCEPT BioRobotics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRCT

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>PROCEPT BioRobotics（纳斯达克代码：PRCT）的股价在周二上涨了 7.4%，达到 28.41 美元，交易量为 588,266 股。分析师对该股票的评级不一，Oppenheimer 维持 “市场表现” 评级，而美国银行则将其下调至 “表现不佳”，目标价为 20 美元。该公司报告的收入同比增长 20.1%，但未能达到每股收益预期。内部交易活动包括显著的买入和卖出。该股票的共识评级为 “持有”，目标价为 41.45 美元</p>

<p>Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) rose 7.4% on Tuesday . The company traded as high as $28.17 and last traded at $28.4110. Approximately 588,266 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 1,533,480 shares. The stock had previously closed at $26.45.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics Corporation（纳斯达克股票代码：PRCT - 获取免费报告）的股票在周二上涨了 7.4%。该公司的股价最高达到 28.17 美元，最后交易价格为 28.4110 美元。在午盘交易中，约有 588,266 股成交，较日均成交量 1,533,480 股下降了 62%。该股票此前收盘价为 26.45 美元。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PROCEPT BioRobotics</strong> 的最新动态：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的机器人股票有望获得巨大收益</li>
</ul>
</div><p>Several research firms have weighed in on PRCT. Oppenheimer reissued a &#34;market perform&#34; rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Robert W. Baird initiated coverage on PROCEPT BioRobotics in a research report on Friday, March 6th. They issued a &#34;neutral&#34; rating and a $30.00 price objective on the stock. Bank of America lowered PROCEPT BioRobotics from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and decreased their target price for the stock from $38.00 to $20.00 in a research note on Thursday, February 26th. Leerink Partners cut their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, February 26th. Finally, Piper Sandler restated an &#34;overweight&#34; rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of &#34;Hold&#34; and a consensus price target of $41.45.</p>
<div class="lb-trans"><p>几家研究公司对 PRCT 进行了评估。Oppenheimer 在 2 月 26 日的研究报告中重新发布了对 PROCEPT BioRobotics 股票的 “市场表现” 评级。Robert W. Baird 在 3 月 6 日的研究报告中开始覆盖 PROCEPT BioRobotics。他们对该股票给予了 “中性” 评级，目标价为 30.00 美元。美国银行在 2 月 26 日的研究报告中将 PROCEPT BioRobotics 的评级从 “中性” 下调至 “表现不佳”，并将目标价从 38.00 美元下调至 20.00 美元。Leerink Partners 在 2 月 26 日的报告中将 PROCEPT BioRobotics 的目标价从 55.00 美元下调至 30.00 美元，并给予该公司 “跑赢大盘” 的评级。最后，Piper Sandler 在 4 月 30 日的研究报告中重申了 “增持” 评级，并将目标价从 28.00 美元上调至 35.00 美元。八位研究分析师对该股票给予了买入评级，四位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，PROCEPT BioRobotics 的共识评级为 “持有”，共识目标价为 41.45 美元。</p>
</div><p><strong>Check Out Our Latest Report on PROCEPT BioRobotics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PROCEPT BioRobotics 的最新报告</strong></p>
</div><h2>PROCEPT BioRobotics Stock Up 7.7%</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票上涨 7.7%</h2>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
</div><p>The company has a market capitalization of $1.62 billion, a PE ratio of -15.66 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The company has a 50-day moving average of $25.06 and a two-hundred day moving average of $29.17.</p>
<div class="lb-trans"><p>该公司的市值为 16.2 亿美元，市盈率为-15.66，贝塔值为 0.83。公司的债务与股本比率为 0.15，流动比率为 6.73，速动比率为 5.51。该公司的 50 日移动平均线为 25.06 美元，200 日移动平均线为 29.17 美元。</p>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The business had revenue of $83.13 million during the quarter, compared to analysts' expectations of $80.52 million. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. PROCEPT BioRobotics's revenue was up 20.1% on a year-over-year basis. Sell-side analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（纳斯达克股票代码：PRCT - 获取免费报告）最近在 4 月 29 日公布了季度财报。该公司报告季度每股收益为（0.56 美元），低于市场共识预期的（0.55 美元）0.01 美元。PROCEPT BioRobotics 的净利润率为-31.82%，股本回报率为-27.70%。该公司在本季度的收入为 8313 万美元，而分析师的预期为 8052 万美元。在去年同期，该公司每股收益为（0.45 美元）。PROCEPT BioRobotics 的收入同比增长了 20.1%。卖方分析师预计 PROCEPT BioRobotics Corporation 在本财年的每股收益将为-1.53 美元。</p>
</div><h2>Insider Transactions at PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 的内部交易</h2>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Intuitive Surgical 的股票在医疗领域占据主导地位</li>
</ul>
</div><p>In other news, EVP Alaleh Nouri sold 5,363 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $25.96, for a total value of $139,223.48. Following the sale, the executive vice president directly owned 105,354 shares of the company's stock, valued at approximately $2,734,989.84. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Antal Rohit Desai bought 98,699 shares of PROCEPT BioRobotics stock in a transaction dated Monday, March 9th. The stock was purchased at an average cost of $24.55 per share, for a total transaction of $2,423,060.45. Following the completion of the acquisition, the director directly owned 426,262 shares of the company's stock, valued at approximately $10,464,732.10. The trade was a 30.13% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 426,262 shares of company stock valued at $10,483,091 and have sold 23,229 shares valued at $573,466. Insiders own 17.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Alaleh Nouri 在 3 月 19 日的交易中出售了 5,363 股 PROCEPT BioRobotics 的股票。该股票以平均价格 25.96 美元出售，总价值为 139,223.48 美元。出售后，该执行副总裁直接持有公司 105,354 股股票，价值约为 2,734,989.84 美元。此次交易使其持股减少了 4.84%。该出售在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事 Antal Rohit Desai 在 3 月 9 日的交易中购买了 98,699 股 PROCEPT BioRobotics 的股票。该股票以每股平均 24.55 美元的价格购买，总交易额为 2,423,060.45 美元。完成收购后，该董事直接持有公司 426,262 股股票，价值约为 10,464,732.10 美元。此次交易使其持股增加了 30.13%。有关此次购买的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士购买了 426,262 股公司股票，价值为 10,483,091 美元，并出售了 23,229 股，价值为 573,466 美元。内部人士持有公司 17.40% 的股份。</p>
</div><h2>Institutional Investors Weigh In On PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>机构投资者对 PROCEPT BioRobotics 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the stock. Prosight Management LP grew its stake in shares of PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company's stock valued at $43,415,000 after buying an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock valued at $122,052,000 after buying an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock valued at $102,919,000 after buying an additional 1,218,815 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in shares of PROCEPT BioRobotics by 229.7% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,128,288 shares of the company's stock valued at $40,269,000 after buying an additional 786,094 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of PROCEPT BioRobotics by 105.2% during the third quarter. Mackenzie Financial Corp now owns 1,454,434 shares of the company's stock valued at $51,909,000 after buying an additional 745,778 shares during the last quarter. 89.46% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对该股票的持股。Prosight Management LP 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 1,692.4%。Prosight Management LP 现在持有 138 万股公司股票，价值 4341.5 万美元，此前在上个季度又购买了 1,303,009 股。Alliancebernstein L.P.在第三季度将其在 PROCEPT BioRobotics 的持股增加了 58.6%。Alliancebernstein L.P.现在持有 3419784 股公司股票，价值 1.22052 亿美元，此前在上个季度又购买了 1,262,928 股。T. Rowe Price Investment Management Inc.在第四季度将其在 PROCEPT BioRobotics 的持股增加了 59.4%。T. Rowe Price Investment Management Inc.现在持有 3271408 股公司股票，价值 1.02919 亿美元，此前在上个季度又购买了 1,218,815 股。ArrowMark Colorado Holdings LLC 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 229.7%。ArrowMark Colorado Holdings LLC 现在持有 1128288 股公司股票，价值 4026.9 万美元，此前在上个季度又购买了 786,094 股。最后，Mackenzie Financial Corp 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 105.2%。Mackenzie Financial Corp 现在持有 1454434 股公司股票，价值 5190.9 万美元，此前在上个季度又购买了 745,778 股。89.46% 的股票由机构投资者持有。</p>
</div><h2>PROCEPT BioRobotics Company Profile</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics, Inc 是一家医疗设备公司，专注于开发和商业化用于治疗良性前列腺增生（BPH）的机器人系统。该公司的技术利用精密机器人和实时成像进行微创手术，旨在减少患者恢复时间，并改善与传统外科方法相比的临床结果。</p>
</div><p>The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.</p>
<div class="lb-trans"><p>该公司的旗舰产品 AquaBeam 机器人系统使用高速水射流选择性去除前列腺组织，同时保护周围健康结构。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
<li>Axon Surged After Earnings and Is Still Down Over 50% From Highs</li>
<li>The Event That Could Redefine Apple’s Summer Rally</li>
<li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 PROCEPT BioRobotics 更好的股票</li>
<li>AST SpaceMobile 因银河第一季度业绩不佳暴跌：垂直整合能拯救这家 SpaceX 竞争对手吗？</li>
<li>Axon 在财报发布后大涨，但仍比高点下跌超过 50%</li>
<li>可能重新定义苹果夏季反弹的事件</li>
<li>Hims &amp; Hers 股票在第一季度业绩不佳后暴跌：GLP-1 的转变足以推动复苏吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 PROCEPT BioRobotics 吗？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PROCEPT BioRobotics 并不在名单上。</p>
</div><p>While PROCEPT BioRobotics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PROCEPT BioRobotics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PROCEPT BioRobotics（NASDAQ:PRCT）股价上涨 7.4% - 是否值得购买？